$0.48
13.84% yesterday
Nasdaq, May 16, 10:00 pm CET
ISIN
US15117N5032
Symbol
IMNN

Celsion Corporation Stock price

$0.48
-0.38 43.81% 1M
-0.21 30.45% 6M
-0.47 49.06% YTD
-0.92 65.44% 1Y
-2.08 81.10% 3Y
-20.67 97.71% 5Y
-556.02 99.91% 10Y
Nasdaq, Closing price Fri, May 16 2025
-0.08 13.84%
ISIN
US15117N5032
Symbol
IMNN
Sector

Key metrics

Market capitalization $7.08m
Enterprise Value $5.22m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 15.65
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-18.27m
Free Cash Flow (TTM) Free Cash Flow $-16.11m
Cash position $2.87m
EPS (TTM) EPS $-1.41
P/E forward negative
Short interest 7.06%
Show more

Is Celsion Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,790 stocks worldwide.

Celsion Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Celsion Corporation forecast:

4x Buy
100%

Analyst Opinions

4 Analysts have issued a Celsion Corporation forecast:

Buy
100%

Financial data from Celsion Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs 0.74 0.74
42% 42%
-
-0.74 -0.74
-
-
- Selling and Administrative Expenses 6.28 6.28
20% 20%
-
- Research and Development Expense 11 11
12% 12%
-
-18 -18
11% 11%
-
- Depreciation and Amortization 0.74 0.74
-
-
EBIT (Operating Income) EBIT -18 -18
10% 10%
-
Net Profit -18 -18
6% 6%
-

In millions USD.

Don't miss a Thing! We will send you all news about Celsion Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Celsion Corporation Stock News

Neutral
GlobeNewsWire
2 days ago
Company's PlaCCine® technology platform demonstrates better durability and other advantages compared to mRNA vaccines
Neutral
Seeking Alpha
5 days ago
Imunon, Inc. (NASDAQ:IMNN ) Q1 2025 Earnings Conference Call May 12, 2025 11:00 AM ET Company Participants Peter Vozzo - ICR Healthcare, Investor Relations Stacy Lindborg - President & Chief Executive Officer Douglas Faller - Chief Medical Officer David Gaiero - Interim Chief Financial Officer Conference Call Participants Emily Bodnar - H.C. Wainwright Laura Suriel - Alliance Global Partners Op...
Neutral
GlobeNewsWire
5 days ago
First site initiated for Phase 3 OVATION 3 study of IMNN-001 in treatment of newly diagnosed advanced ovarian cancer New data from Phase 2 OVATION 2 study of IMNN-001 accepted for oral presentation at 2025 ASCO Annual Meeting Company to hold conference call today at 11:00 a.m. ET LAWRENCEVILLE, N.J.
More Celsion Corporation News

Company Profile

Celsion Corp . is a clinical stage oncology drug company. It focuses on cancer treatments, including directed chemotherapies, DNA-mediated immunotherapy and RNA-based therapies. The firm engages in the research and development of pharmaceutical products for cancer treatments. Its portfolio includes deoxyribonucleic acid-mediated immunotherapy and ribonucleic acid-based therapies. It operates through the Celsion and ThermoDox brands. The company was founded by Yim-Pan Cheung in 1982 and is headquartered in Lawrenceville, NJ.

Head office United States
CEO Stacy Lindborg
Employees 25
Founded 1982
Website imunon.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today